2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Carcinoma, Non-Small-Cell Lung
464
Melanoma
300
Squamous Cell Carcinoma of Head and Neck
234
Parkinson Disease 4, Autosomal Dominant Lewy Body
189
Neoplasms
185
Triple Negative Breast Neoplasms
163
Breast Neoplasms
162
Neoplasm Metastasis
157
Lung Neoplasms
147
Colorectal Neoplasms
142
Carcinoma, Renal Cell
132
Head and Neck Neoplasms
123
Stomach Neoplasms
104
Ovarian Neoplasms
101
Carcinoma, Transitional Cell
91
Urinary Bladder Neoplasms
81
Pancreatic Neoplasms
81
Endometrial Neoplasms
74
Carcinoma, Hepatocellular
74
Uterine Cervical Neoplasms
63
Esophageal Neoplasms
57
Recurrence
52
Prostatic Neoplasms
49
Sarcoma
43
Carcinoma
42
Glioblastoma
40
Small Cell Lung Carcinoma
39
Carcinoma, Squamous Cell
39
Hodgkin Disease
36
Cholangiocarcinoma
35
Interventions
lutetium Lu 177 dotatate
8
lanreotide
4
copper dotatate CU-64
4
Octreotide
4
177Lu-octreotide, DOTA(0)-Tyr(3)-
4
pasireotide
3
Magnetic Resonance Spectroscopy
3
Lutetium-177
3
Lutetium
3
gallium Ga 68 dotatate
2
amino-acid, glucose, and electrolyte solution
2
Temozolomide
2
Nivolumab
2
Irinotecan
2
Ga(III)-DOTATOC
2
Everolimus
2
Etoposide
2
Carboplatin
2
zimberelimab
1
regorafenib
1
pembrolizumab
1
irinotecan sucrosofate
1
folfirinox
1
famitinib
1
cabozantinib
1
arginyllysine
1
abemaciclib
1
X-Rays
1
Sunitinib
1
Somatostatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Gastro-enteropancreatic neuroendocrine tumor
×
pembrolizumab
×
Clear all
NCT03043664
2023-06-29
PLANET
Duke University
Phase 1/2
Completed
22 enrolled
12 charts